JP2024539212A - キナゾリン誘導体の結晶形態、調製、組成物およびその使用 - Google Patents

キナゾリン誘導体の結晶形態、調製、組成物およびその使用 Download PDF

Info

Publication number
JP2024539212A
JP2024539212A JP2024523839A JP2024523839A JP2024539212A JP 2024539212 A JP2024539212 A JP 2024539212A JP 2024523839 A JP2024523839 A JP 2024523839A JP 2024523839 A JP2024523839 A JP 2024523839A JP 2024539212 A JP2024539212 A JP 2024539212A
Authority
JP
Japan
Prior art keywords
crystalline form
type
free base
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539212A5 (https=
Inventor
チョン ワン，
ディン チョウ，
ツーチアン チョン，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2024539212A publication Critical patent/JP2024539212A/ja
Priority to JP2025175882A priority Critical patent/JP2026027273A/ja
Publication of JP2024539212A5 publication Critical patent/JP2024539212A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024523839A 2021-10-20 2022-10-19 キナゾリン誘導体の結晶形態、調製、組成物およびその使用 Pending JP2024539212A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025175882A JP2026027273A (ja) 2021-10-20 2025-10-17 キナゾリン誘導体の結晶形態、調製、組成物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021125016 2021-10-20
CNPCT/CN2021/125016 2021-10-20
PCT/CN2022/126169 WO2023066296A1 (en) 2021-10-20 2022-10-19 Crystalline forms of quinazoline derivatives, preparation, composition and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025175882A Division JP2026027273A (ja) 2021-10-20 2025-10-17 キナゾリン誘導体の結晶形態、調製、組成物およびその使用

Publications (2)

Publication Number Publication Date
JP2024539212A true JP2024539212A (ja) 2024-10-28
JP2024539212A5 JP2024539212A5 (https=) 2025-10-27

Family

ID=86057927

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024523839A Pending JP2024539212A (ja) 2021-10-20 2022-10-19 キナゾリン誘導体の結晶形態、調製、組成物およびその使用
JP2025175882A Pending JP2026027273A (ja) 2021-10-20 2025-10-17 キナゾリン誘導体の結晶形態、調製、組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025175882A Pending JP2026027273A (ja) 2021-10-20 2025-10-17 キナゾリン誘導体の結晶形態、調製、組成物およびその使用

Country Status (25)

Country Link
US (1) US20240417403A1 (https=)
EP (2) EP4399207B1 (https=)
JP (2) JP2024539212A (https=)
KR (1) KR20240090181A (https=)
CN (4) CN119317625A (https=)
AU (1) AU2022371540A1 (https=)
CA (1) CA3232101A1 (https=)
CL (1) CL2024001231A1 (https=)
CO (1) CO2024004745A2 (https=)
CR (1) CR20240163A (https=)
DK (1) DK4399207T3 (https=)
ES (1) ES3059167T3 (https=)
FI (1) FI4399207T3 (https=)
HR (1) HRP20260049T1 (https=)
IL (1) IL312004A (https=)
LT (1) LT4399207T (https=)
MA (1) MA66471B1 (https=)
MX (1) MX2024004738A (https=)
PE (1) PE20242106A1 (https=)
PL (1) PL4399207T3 (https=)
PT (1) PT4399207T (https=)
RS (1) RS67641B1 (https=)
SI (1) SI4399207T1 (https=)
SM (1) SMT202600023T1 (https=)
WO (1) WO2023066296A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2025195333A1 (en) 2024-03-19 2025-09-25 F. Hoffmann-La Roche Ag Pharmaceutical formulation of erbb2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020057511A1 (en) * 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ATE446294T1 (de) * 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
EP3516071B1 (en) * 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
TWI858848B (zh) * 2018-05-08 2024-10-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020057511A1 (en) * 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005767396 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6018028449, 2002, pages 56 - 102, ISSN: 0005769488 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005767397 *

Also Published As

Publication number Publication date
ES3059167T3 (en) 2026-03-19
PT4399207T (pt) 2026-01-16
SMT202600023T1 (it) 2026-03-09
JP2026027273A (ja) 2026-02-18
KR20240090181A (ko) 2024-06-21
FI4399207T3 (fi) 2026-01-28
CN120309620A (zh) 2025-07-15
CA3232101A1 (en) 2023-04-27
CN120309621A (zh) 2025-07-15
CN119317625A (zh) 2025-01-14
CO2024004745A2 (es) 2024-04-29
SI4399207T1 (sl) 2026-04-30
RS67641B1 (sr) 2026-02-27
EP4399207A4 (en) 2025-03-19
LT4399207T (lt) 2026-02-10
HRP20260049T1 (hr) 2026-02-27
AU2022371540A1 (en) 2024-03-21
DK4399207T3 (da) 2026-02-02
MX2024004738A (es) 2024-05-14
PE20242106A1 (es) 2024-10-28
IL312004A (en) 2024-06-01
CN120623183A (zh) 2025-09-12
CR20240163A (es) 2024-06-12
MA66471B1 (fr) 2026-02-27
WO2023066296A1 (en) 2023-04-27
EP4399207A1 (en) 2024-07-17
US20240417403A1 (en) 2024-12-19
EP4399207B1 (en) 2025-11-26
PL4399207T3 (pl) 2026-03-23
CL2024001231A1 (es) 2024-08-09
EP4717689A2 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
JP7324862B2 (ja) Ｅｇｆｒ阻害剤の結晶体およびその調製方法
US9375432B2 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US8673912B2 (en) Crystalline Forms on N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US10765678B2 (en) Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them
JP2026027273A (ja) キナゾリン誘導体の結晶形態、調製、組成物およびその使用
US20230271936A1 (en) Efgr inhibitor, preparation method therefor and application thereof
TW201236684A (en) Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
JP2021517902A (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
BR112013008523B1 (pt) Compostos de piridazina carboxamida substituídos e usos dos mesmos para tratar câncer, uma doença de proliferação, uma doença neurológica, uma doença psiquiátrica, obesidade, diabetes ou doença cardiovascular
TWI796250B (zh) 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
JP2020526593A (ja) Ｎ−フェニル−２−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法
WO2017162611A1 (en) Quinoline-3-carboxamide compounds and their use in treating cancer
HK40124039A (zh) 喹唑啉衍生物的结晶形式、其制备、组合物和用途
HK40123142A (zh) 喹唑啉衍生物的结晶形式、其制备、组合物和用途
HK40115474A (zh) 喹唑啉衍生物的结晶形式、其制备、组合物和用途
EA052616B1 (ru) Кристаллические формы производных хиназолина, их получение, композиции и применение
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2024032615A1 (zh) 吡啶并嘧啶酮化合物的晶型、其酸式盐、其酸式盐的晶型和用途
JP2025541949A (ja) ジオキサンキノリン化合物の塩、その結晶形、その調製方法、及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406